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Endocrine therapy has a key role in the treatment of metastatic
breast cancer. While oestrogens given in pharmacological doses
have been known for decades to cause antitumour effects (Haddow
et al, 1944; Carter et al, 1977), they were replaced by tamoxifen in
the late 1970s. The reason to this was the lower toxicity of the
antioestrogen, while the 2 regimens were considered to be equally
effective with respect to tumour response (Ingle et al, 1981). Long-
term follow-up results have suggested diethylstilboestrol to be
more effective than tamoxifen (Peethambaram et al, 1999). 
The mechanisms by which oestrogens in high doses cause anti-
tumour effects in breast cancer are not known. However, in vitro
studies have focused on the importance of cross-talk between
steroids and growth factors, in particular the insulin like growth
factors (IGFs), to breast cancer growth (Westley and May, 1994;
Lee et al, 1997). 
IGF-I is a potent mitogen to breast cancer cell lines in vitro
(Karey and Sirbasku, 1988) and high plasma levels of IGF-I has
been reported to be a risk factor for breast cancer development in
premenopausal women (Hankinson et al, 1998). Inhibition of IGF-I
receptor activation by antibodies or antisense strategies has been
shown to cause antitumour effects in animal models (Arteaga et al,
1989; Dunn et al, 1998). IGF-I and -II are expressed by many
different tissues and may thus act by both paracrine and autocrine
mechanisms in addition to the large circulating plasma pool of
peptides (Daughaday and Rotwein, 1989). In addition, the
bioavailability of IGF-I as well as IGF-II to the tissues may be
influenced by plasma levels of the 6 different IGF-binding
proteins (IGFBPs), IGFBP related proteins, phosphorylation status
of the IGFBPs as well as IGFBP-protease activity (Jones and
Clemmons, 1995; Hwa et al, 1998). About 99% of IGF-I and IGF-II
are found in a ternary complex consisting of IGF-I or -II, IGFBP-3
(the major IGFBP in plasma) and an acid labile subunit (ALS).
Thus, only a minor fraction of circulating IGFs is free (or easily
dissociable) and therefore available to the tissues. Release of IGF-I
from the circulating pool may be facilitated through increased
activity of IGFBP-3 proteases, reducing the binding affinity of
IGF-I to the ternary complex (Lassarre and Binoux, 1994).
Increased IGFBP-3 protease activity is observed in several clinical
conditions including advanced breast cancer (Giudice et al, 1990;
Müller et al, 1993; Bereket et al, 1995; Cotterill et al, 1996; Frost
et al, 1996). 
Previous studies have revealed oral administration of oestrogens
for hormone substitution (Weissberger et al, 1991; Helle et al,
1996c) as well as the SERMS tamoxifen and droloxifene (Colletti
et al, 1989; Lønning et al, 1992; Helle et al, 1996a) to cause a
moderate reduction in total IGF-I but elevated IGFBP-I. However,
the effect of oestrogens in pharmacological doses on the IGF-
system has not been reported previously. 
To evaluate potential alterations in the IGF-system in breast
cancer patients receiving oestrogens in pharmacological doses, we
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teins and IGFBP-3 protease activity in 16 patients suffering from
metastatic breast cancer before and during treatment with diethyl-
stilboestrol 5 mg 3 times daily. 
SUBJECTS AND METHODS 
Patients 
16 postmenopausal women with progressive metastatic breast
cancer failing multiple endocrine regimens were enrolled in a
phase II study evaluating treatment with diethylstilboestrol 5 mg 
3 times daily. The median age was 72 years (range 52–87), and
the number of previous endocrine regimens ranged from 3 to 10
(median 4). Last treatment before diethylstilboestrol therapy and
the length of the washout period (time between last dose of their
previous therapy and pre-treatment blood sampling) is given in
Table 1. The clinical results are to be reported elsewhere as a 
2-centre study (Lønning et al, 2001). The study was approved by
the regional ethical committee. 
Blood sampling 
Fasting blood samples (heparinized vials) were obtained before
treatment and after 2 weeks, 1 month and/or 2–3 months during
treatment with diethylstilboestrol. Samples were centrifugated
within 20 minutes and plasma aliquots stored at –20 C until
analysis. 
Materials 
Human recombinant IGF-I and IGF-II were purchased from
GroPep (Adelaide, Australia). IGF-I and IGF-II were iodinated
using the chloramine-T method. Labelled peptide was separated
from non-incorporated 125I by AcA 202 columns (BioSepra,
Villeneuve, France) using 1 ´ 40 cm columns. 
Assays 
Plasma levels of IGF-I and IGF-II (Frost et al, 1996) were
measured by RIA following acid-acetone extraction (Bowsher 
et al, 1991). Intra-and inter-assay coefficients of variations were
3.5% and 6.2% for IGF-I and 5.5% and 12.9% for IGF-II, respec-
tively. Commercial kits (IRMA/RIA) for free IGF-I, IGFBP-I,
IGFBP-2, and IGFBP-3 were purchased from Diagnostic System
Laboratories (Webster, TX), and the measurements were made
according to the manufacturer’s instructions. 
The IGFBP profile in the plasma was analysed by Western ligand
blotting (WLB) using a modified version (Coulson et al, 1991) of the
technique originally developed by Hossenlopp (Hossenlopp et al,
1986).  125I labelled IGF-I and IGF-II was used as tracer binding IGF-
binding proteins on the membrane. Radiolabelled IGFBPs were
visualized by autoradiography and quantified using a densitometric
scanner (Pharmacia LKB, Uppsala, Sweden). The IGFBP pattern
was compared with the profile of a normal plasma pool (NP), and
samples from each patient were analysed in the same run for compar-
ison. In order to analyse for IGFBP-3 proteolysis, the membranes
were immunoblotted (after WLB) using a polyclonal antiserum
against IGFBP-3 purchased from Diagnostic Systems Laboratories
(Webster, TX) at a final dilution of 1:10 000. The membranes were
then developed (showing intact IGFBP-3 as well as fragments) using
enhanced chemiluminescent reagents supplied byAmersham
(Aylesbury, UK) according to the manufacturer’s instruction, and the
films subjected to densitometric scanning. IGFBP-3 protease activity
was measured indirectly as IGFBP-3 fragmentation, defined as the
ratio of the major IGFBP-3 fragment (30kDa) to total IGFBP-3 eval-
uated by densitometric scanning of immunoblots. 
Statistics 
Testing for distribution of the different IGF parameters with Q–Q
plots in our normal populations of pre- and postmenopausal
women revealed all parameters to be best fitted to a log normal
distribution with the exception of IGFBP-3 protease activity. This
parameter was best described by a normal distribution. Thus,
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Table 1 Demographic and clinical data of patients included in the study 
Patient no. Age (years) No. of previous  Last treatment  Response to DES Washout period (days) 
endocrine regimens before DES
1 86 3 Formestane CR 30 
2 53 6 Formestane PD 8 
3 65 3 Tamoxifen PR 47 
4 73 4 Exemestane PD 14 
5 74 5 Anastrozole PR 14 
6 76 5 Tamoxifen SD 27 
7 71 4 Anastrozole PD 30 
8 70 10 Anastrozole SD 21 
9 62 3 MA PR 21 
10 70 5 Formestane PD 24 
11 79 3 MA + Formestane CR 14 
12 87 5 Tamoxifen PR 42 
13 80 5 Tamoxifen CR 791 
14 72 5 Tamoxifen SD 19 
15 72 3 MA CR 30 
16 68 3 Aminoglutethimide PR 36 
Response was evaluated according to the UICC criteria; CR = complete response, PR = partial response, SD = stable disease, 
> 3 months, PD = progressive disease. MA = megestrol acetate. Washout period = time period from stopping last endocrine regimen to
commencement of diethylstilbestrol. parameters obtained in the different groups of patients are given as
their geometric mean value with 95% confidence intervals of the
mean, with the exception of IGFBP-3 protease activity where the
arithmetic mean values are given. Considering statistical differ-
ence from pre-treatment levels, on-treatment values are signifi-
cantly different when the confidence interval of the mean does not
span the mean pretreatment value. P values were calculated using
the Friedmans test (non-parametric analysis of variance). 
RESULTS 
9 patients obtained a partial or a complete response to treatment, 
3 stable disease, while progressive disease was observed in 4
patients. Median time to progression was 18 weeks. 
Alterations in the different IGF-parameters during treatment
with diethylstilboestrol are shown in Table 2. The findings may be
summarized as follows. 
Treatment with diethylstilboestrol suppressed plasma IGF-I to a
mean value of 56–66% of pretreatment levels (P < 0.001), IGF-II
to 60–67% of pretreatment levels (P < 0.001) and free IGF-I
to 25–31% of its pretreatment values (P < 0.001). Similarly,
we observed a decrease in plasma IGFBP-2 to 53–69% of
its pretreatment values as measured by RIA (P = 0.001),
and 57–80% of pretreatment values when evaluated by Western
ligand blot (P = 0.0025). We also observed a decrease in IGFBP-3
measured by RIA (69–74% of pretreatment values; P = 0.001), and
Western ligand blot (61–84% of pretreatment values; P = 0.07), as
well as a decrease in IGFBP-3 protease activity (mean decrease of
22–29%;  P = 0.03). In contrast, plasma levels of IGFBP-1
measured by RIA and IGFBP-4 measured by Western ligand blot
both increased (IGFBP-1 to 250–273% of pretreatment values; P =
0.001, and IGFBP-4 to 140–150% of pretreatment values; P = 0.03).
Previous treatment could potentially affect the results for patients
number 2, 6 and 14. However, eliminating these patients had no
influence on the results with the exception of IGFBP-3 protease
activity, where the significant decrease in this parameter was lost. 
Representative Western ligand blots and immunoblots are
shown in Figure 1. For most parameters these alterations were
fully developed after 2 weeks on treatment. Comparing patients
obtaining a clinical response (CR or PR), stable disease, and
progressive disease did not reveal any significant differences in
the measured parameters between these patient groups. 
DISCUSSION 
Plasma levels of the different IGF-parameters measured before
treatment were in the same range as previously reported by our
group (Frost et al, 1996). Although some patients had short
washout time, it is unlikely that previous treatment has significant
impact on our results as most of these patients had received
formestane, exemestane or anastrozole. Formestane (Frost et al,
1996) and exemestane (unpublished observations by our group)
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Figure 1 Western ligand blots (A) with corresponding immunoblots
(B) from 3 patients before and during treatment with diethylstilboestrol. As
these patients had a decrease in IGFBP-3 protease activity during treatment,
alterations in intact IGFBP-3 do not reflect the fall in total 16FBP-3 observed
in the whole treatment group 
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Table 2 Values of IGF-I, F-IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 measured by RIA/IRMA, and IGFBP-2, -3 and -4
by Western ligand blot before treatment, and percentage of pretreatment levels/percentage change at various intervals during
treatment with diethylstilboestrol. IGFBP-3 protease activity is measured indirectly as the ratio of fragmented to total IGFBP-3
on immunoblots. Values are given as geometrical mean values (with 95% confidence intervals) with the exception of IGFBP-3
protease where arithmetic values are given. During treatment alterations in IGFBP-3 protease activity are given as
percentage change, while the other parameters are given as percentage of pretreatment values 
Measured levels (nmol l–1) percentage change/percentage of pretreatment levels 
Before treatment (n = 16) 2 weeks (n = 12) 1 month (n = 14) 2–3 months (n = 14) 
IGF-I 12.8 (10.6–15.5) 63 (49–79) 56 (44–73) 66 (53–82) 
IGF-II 64.4 (51.3–80.9) 67 (56–80) 60 (52–68) 64 (55–75) 
F-IGF-I 0.10 (0.08–0.14) 29 (19–42) 25 (18–36) 31 (21–46) 
IGFBP-1 RIA 1.5 (0.7–3.0) 250 (127–495) 273 (138–542) 273 (146–510) 
IGFBP-2 RIA 29.6 (23.1–38.0) 53 (18–156) 69 (61–78) 66 (57–78) 
IGFBP-2* WLB 5.1 (2.9–8.8) 80 (65–99) 68 (52–88) 57 (44–74) 
IGFBP-3 RIA 94.6 (82.9–106.3) 74 (63–85) 69 (62–76) 71 (63–80) 
IGFBP-3* WLB 75 (57–97) 84 (64–110) 61 (45–82) 69 (52–92) 
IGFBP-3** PROT 0.35 (0.30–0.42) –29 (–46 –5)*** –22 (–36 –6)*** –29 (–46 –7)***
IGFBP-4* WLB 3.7 (2.7–5.1) 146 (112–192) 140 (116–169) 150 (114–198) 
*Arbitrary units. **Ratio of fragmented to total IGFBP-3. n = number of observations.
*** Percentage change from pretreatment levels.have been shown to have little effects on plasma IGF-I, while no
data exists on anastrozole. 
The moderate reduction in total IGF-I (30–40%) found in this
study is in the range previously reported for oral oestrogens
administered in doses regularly used for hormone replacement
(Weissberger et al, 1991; Helle et al, 1996c), and during treatment
with tamoxifen (Colletti et al, 1989; Helle et al, 1996b) or drolox-
ifene (Helle et al, 1996a) in breast cancer patients. While these
drugs also cause an increase in IGFBP-1 (Lønning et al, 1992;
Helle et al, 1996a), the magnitude of this increase seems smaller
with droloxifene, tamoxifen and hormone replacement therapy
compared to that which we describe here. This may be related to
drug doses for tamoxifen and droloxifene but also to the relative
oestrogen agonistic versus antagonistic effects of these drugs.
Tamoxifen has oestrogen agonistic effects on hepatic synthesis of
sex hormone-binding globuline, thyroxin-binding globuline as
well as lipoproteins (Fex et al, 1981; Love et al, 1991) and this
drug is found to inhibit IGF-I gene expression in the liver (Huynh
et al, 1993). Thus it is likely that the effects on plasma IGF-I levels
(and possibly some IGFBPs) are due to oestrogen agonistic effects
of diethylstilboestrol on hepatic synthesis. 
Findings from in vitro studies are of limited value to explain the
effects of diethylstilboestrol on plasma IGF-II and IGF-binding
proteins. Oestradiol has been reported to increase expression of
IGF-II (Lee et al, 1994), IGFBP-2 (Pratt and Pollak, 1993) and
enhance the secretion of IGFBP-3 proteases (Salahifar et al, 2000)
in breast cancer cell lines, while the opposite effects on plasma
levels of these parameters are observed in this study. 
The significant reduction in plasma IGF-II (30–40%) observed
here, has not been recorded previously during therapy with oestro-
gens or anti-oestrogens. In contrast to IGF-I, IGF-II has not been
considered a subject to regulation by endocrine drugs. The
decrease in IGF-II observed in this study may be secondary to
a decrease in IGFBP-3, which is also observed during treatment
with oral oestrogens in replacement doses (Kam et al, 2000) as
well as somatostatin analogues (Helle et al, 1998). However, in
contrast to somatostatin analogues which decrease plasma growth
hormone (GH) levels, the opposite effect is found during treatment
with diethylstilboestrol (Bishop et al, 1985). 
To our knowledge, free IGF-I has not been measured in
previous studies evaluating the effect of endocrine treatment on
the IGF-system. Here, we observed a drop in plasma levels of free
IGF-I to a mean value of 25–31% of its pretreatment level. The
decrease in free IGF-I may be somewhat more pronounced than
expected based on the moderate decrease in total IGF-I. The
observed decrease in IGFBP-3 protease activity may to some
extent explain this finding, as the IGFBP-3 protease may facilitate
release of IGF-I from the ternary complex (Lassarre and Binoux,
1994). The commercial IRMA kit used for measurement of free
IGF-I in this study in general measures somewhat higher levels
compared to what is recorded with use of ultrafiltration, probably
due to inclusion of some easily dissociable IGF-I (Frystyk et al,
1999). However, the value most likely reflects the amount of IGF-
I readily available to the tissues. It is also possible that increase in
plasma levels of IGFBP-1 and IGFBP-4 may contribute to the
reduced levels of free IGF-I. A greater suppression of free IGF-I,
compared to total IGF-I, may indicate that free IGF-I measurement
has more value as a surrogate marker for IGF-I bioavailability for
breast cancer patients treated with endocrine therapy. 
A moderate reduction in IGFBP-3 protease was observed. The
patients included in the study in general had a low metastatic
tumour burden and a slowly progressive disease. A high number of
our patients responded to therapy with diethylstilboestrol, and we
have recorded a decrease in IGFBP-3 protease activity for patients
responding to tamoxifen (Helle et al, 1996b). A decrease in
IGFBP-2 was also observed. Increased IGFBP-2 levels have been
previously described for patients with prostate cancer (Cohen et al,
1993; Kanety et al, 1993). The mechanism behind the alterations
in IGFBP-2 is not known, but there seems to be a strong positive
correlation between IGFBP-3 protease activity and IGFBP-2
levels (unpublished observations). Thus, a decrease in IGFBP-2
may partly reflect a decrease in tumour burden during therapy. 
The mechanisms by which oestrogens in high doses cause anti-
tumour effects in breast cancer is unknown, but in vitro studies
have shown a biphasic response curve for breast cancer cells with
oestrogens in high concentrations being toxic to tumour cell
growth (Lippman et al, 1976; Masamura et al, 1995). Also, there is
evidence that oestrogens in high concentrations may induce apop-
tosis in vivo (Song et al, 2000). The toxicity threshold is lowered
as an adaptive process during oestrogen deprivation (Masamura 
et al, 1995). Whether components of the IGF-system may be
involved in these mechanisms is not known. The induction of the
IGF-I receptor as well as the insulin receptor substrate-1 by oestro-
gens in breast cancer cell lines may indicate synergistic effects
between these systems. (Stewart et al, 1990; Molloy et al, 2000).
There is also evidence that IGF-I signalling may be necessary for
maximal oestrogen receptor activation in some human breast
cancer cell lines (Lee et al, 1997). The profound decrease in free
IGF-I, and decrease in both IGF-I and -II, observed in this study,
may be a part of the mechanism of action of this drug in breast
cancer. However, further studies are needed to evaluate the
complex interactions between oestrogens and the IGF-system in
human breast cancer. 
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